ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Gain Therapeutics Inc

Gain Therapeutics Inc (GANX)

1.79
0.08
(4.68%)
Closed December 06 4:00PM
1.79
0.00
( 0.00% )
Pre Market: 7:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.79
Bid
1.85
Ask
1.98
Volume
98
0.00 Day's Range 0.00
0.89 52 Week Range 5.33
Market Cap
Previous Close
1.79
Open
-
Last Trade
50
@
1.87
Last Trade Time
07:55:40
Financial Volume
-
VWAP
-
Average Volume (3m)
328,288
Shares Outstanding
26,525,068
Dividend Yield
-
PE Ratio
-2.15
Earnings Per Share (EPS)
-0.83
Revenue
55k
Net Profit
-22.11M

About Gain Therapeutics Inc

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applicatio... Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across, several therapeutics areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders and oncology. The company has filed four patent applications for novel small molecule drug candidates that are Structurally Targeted Allosteric Regulators (STARs). The company derives revenues from collaboration and licensing agreements. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
Gain Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GANX. The last closing price for Gain Therapeutics was $1.79. Over the last year, Gain Therapeutics shares have traded in a share price range of $ 0.89 to $ 5.33.

Gain Therapeutics currently has 26,525,068 shares outstanding. The market capitalization of Gain Therapeutics is $47.48 million. Gain Therapeutics has a price to earnings ratio (PE ratio) of -2.15.

GANX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.05-2.717391304351.841.871.573363661.74265832CS
4-0.41-18.63636363642.22.251.562658851.78630954CS
120.3423.44827586211.453.191.363282882.08451521CS
26-0.41-18.63636363642.23.190.893693051.59281885CS
52-1.03-36.5248226952.825.330.892565472.17757583CS
156-4.4-71.08239095326.196.70.891285072.76022064CS
260-9.43-84.046345811111.2217.930.891230533.90908165CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LDTCLeddarTech Holdings Inc
$ 0.892
(187.56%)
19.17M
ZEOZeo Energy Corporation
$ 3.04
(132.06%)
25.73M
MSPRMSP Recovery Inc
 2.79
(74.38%)
17.27k
GXAIGaxos ai Inc
$ 3.79
(45.77%)
8.54M
ASSTAsset Entities Inc
$ 0.6476
(40.81%)
8.62M
BIOABioAge Labs Inc
$ 5.84
(-70.93%)
187.3k
UPCUniverse Pharmaceuticals Inc
$ 1.59
(-53.10%)
1.07M
CYNCYNGN Inc
$ 3.95
(-33.72%)
24.8k
SQFTPresidio Property Trust Inc
$ 0.51
(-24.44%)
45.77k
COGTCogent Biosciences Inc
$ 7.15
(-19.57%)
61.37k
RIMEAlgorhythm Holdings Inc
$ 0.1172
(27.39%)
65.23M
RGTIRigetti Computing Inc
$ 5.17
(18.04%)
26.66M
ZEOZeo Energy Corporation
$ 3.03
(131.30%)
25.73M
LDTCLeddarTech Holdings Inc
$ 0.9037
(191.33%)
19.22M
DUOFangDD Network Group Ltd
$ 0.7827
(35.37%)
18.73M

GANX Discussion

View Posts
Gary Ray Gary Ray 2 months ago
$2 long ago
Not going any further
👍️0
1984ISHERE 1984ISHERE 2 months ago
2 now good luck
👍️0
1984ISHERE 1984ISHERE 2 months ago
Don't see it going back there any time soon maybe low 1.20s but even that is doubtful, trend has turned UP
👍️0
Gary Ray Gary Ray 2 months ago
I say likely $1.00 soon

I might buy back in around 60 cent retracement levels
👍️0
silverman8 silverman8 2 months ago
we will likely see $2.55 next week. BAM
👍️ 1
1984ISHERE 1984ISHERE 2 months ago
Parkinson update

https://www.globenewswire.com/news-release/2024/09/26/2953660/0/en/Gain-Therapeutics-To-Host-Virtual-Webinar-on-Results-From-Phase-1-Study-and-Design-of-Upcoming-Phase-1b-Trial-of-GT-02287-a-Novel-GCase-Targeting-Small-Molecule-Therapy-for-Parkins.html
👍️ 1
1984ISHERE 1984ISHERE 2 months ago
Looks like about to take another LEG higher
👍️0
silverman8 silverman8 3 months ago
seems like we are due for a news release soon.
fingers crossed!
👍️0
1984ISHERE 1984ISHERE 3 months ago
Nice 50% move if u were paying attention
👍️0
1984ISHERE 1984ISHERE 3 months ago
Hanging over 1, so you know someone is watching out
👍️0
1984ISHERE 1984ISHERE 4 months ago
I bought some recently in the .90s, only Regret i didn't buy more now 1.50 prints yesterday
👍️0
Monksdream Monksdream 4 months ago
GANX new 52 week low
👍️0
Monksdream Monksdream 5 months ago
GANX new 52 week low
👍️0
1984ISHERE 1984ISHERE 7 months ago
Market Blood Bath 2.95 LOD =]
👍️0
1984ISHERE 1984ISHERE 7 months ago
2.95 today pickUP opportunity =] as Market Down Huge Blood Everywhere
👍️0
Monksdream Monksdream 8 months ago
GANX under $4
👍️0
Monksdream Monksdream 9 months ago
GANX 10Q due 3/26
👍️0
1984ISHERE 1984ISHERE 10 months ago
Been on fire move 5.29 high
Ok to take a rest
👍️0
Sonic Boom Sonic Boom 10 months ago
Darn, looking good $GANX
👍️0
peteypickem peteypickem 10 months ago
GANX $4.60
👍️0
peteypickem peteypickem 10 months ago
GANX $4.50
👍️0
1984ISHERE 1984ISHERE 11 months ago
1 thing is sure a cure is needed
Stock has fallen back under 4 again
👍️0
1984ISHERE 1984ISHERE 11 months ago
1 thing is sure a cure is needed
Stock has fallen back under 4 again
👍️0
peteypickem peteypickem 11 months ago
$GANX $4 break
👍️0
peteypickem peteypickem 11 months ago
#GANX $3.77
👍️0
peteypickem peteypickem 11 months ago
$GANX $3.66,,
👍️0
peteypickem peteypickem 11 months ago
$GANX $3.50
👍️0
peteypickem peteypickem 11 months ago
$GANX $3.27
👍️0
peteypickem peteypickem 11 months ago
GANX $3.20
👍️0
peteypickem peteypickem 11 months ago
GANX $3.05
👍️0
peteypickem peteypickem 11 months ago
Going higher
👍️0
peteypickem peteypickem 11 months ago
GANX $2.97
👍️0
Alias12345 Alias12345 11 months ago
Holy chit, I'm up over 9% in less than a week and it looks like it just might keep going in this direction with periods of consolidation. Thank you petey for the x post on the 14th. Took a look, bought some last week, very happy.
👍️0
peteypickem peteypickem 1 year ago
GANX $2.77
👍️0
peteypickem peteypickem 1 year ago
GANX $2.69
👍️0
peteypickem peteypickem 1 year ago
GANX $2.55
👍️0
peteypickem peteypickem 1 year ago
GANX —- $2.42
👍️0
peteypickem peteypickem 1 year ago
GANX $2.35
👍️0
1984ISHERE 1984ISHERE 2 years ago
just hovering 4.90-5 range
👍️0
1984ISHERE 1984ISHERE 2 years ago
Holding over 5 - Great News Lately For Longs To Be Excited

https://finance.yahoo.com/news/gain-therapeutics-awarded-chf-2-131500689.html
👍️0
THEMASTERS_SON THEMASTERS_SON 3 years ago
,,,,,,,REVERSAL OF FORTUNE!!! OUCH
👍️0
RoadShowPartner RoadShowPartner 3 years ago
Zoom presentation with Gain Therapeutics (Nasdaq: GANX) this Wednesday, 9/22 @ 4:00pm ET . The CEO Eric Richman will be updating investors and answering questions. Please register to attend the presentation using the link below:

https://www.eventbrite.com/e/gain-therapeutics-inc-webinar-9222021-registration-173949637047?utm_source=eventbrite&utm_medium=email&utm_content=follow_notification&utm_campaign=following_published_event&utm_term=Gain+Therapeutics%2C+Inc.-Webinar+9%2F22%2F2021&aff=ebemoffollowpublishemail
👍️0
ProfitScout ProfitScout 3 years ago
Gain Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

September 17, 2021 (Globe Newswire)

- Conference Dates: September 20-23 -

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Date: Wednesday, September 22
Time: 1:15 to 1:55 p.m. ET
Presenter: Eric Richman, Chief Executive Officer
Webcast: Registration Link - Click Here
* a replay will be available following the presentation for 90 days
Please contact your representative at Oppenheimer & Co. to schedule a virtual one-on-one meeting with Gain Therapeutics during the respective conference.

For more information about the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit, please refer to the conference website.

About Gain Therapeutics, Inc.

Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx(TM) target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.

For more information, please visit https://www.gaintherapeutics.com

Forward-Looking Statements

Any statements in this release that are not historical facts may be considered to be "forward-looking statements." Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for Gain's product candidates, and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those expected include Gain's ability to: make commercially available its products and technologies in a timely manner or at all; enter into strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate and manage its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contacts:

Gain Therapeutics Investor Contact:

Daniel Ferry

LifeSci Advisors

+1 (617) 430-7576

daniel@lifesciadvisors.com

Gain Therapeutics Media Contact:

Joleen Schultz

Joleen Schultz & Associates

+1 760-271-8150

joleen@joleenschultzassociates.com
👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit and invites investors to participate via webcast and in one-on-one meetings. Please see additional details below:

https://finance.yahoo.com/news/gain-therapeutics-present-oppenheimer-fall-120000696.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
👍️0
StockHighAlert- StockHighAlert- 3 years ago
Nice green start here $GANX
👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.

https://finance.yahoo.com/news/gain-therapeutics-present-2021-international-202000645.html
👍️0
lockstock31 lockstock31 3 years ago
Running!
👍️0
Trooperstocks Trooperstocks 3 years ago
Very nice news. $GANX announced this afternoon that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.
👍️0
ProfitScout ProfitScout 3 years ago
Gain Therapeutics to Present at 2021 International Virtual GM1 Community Conference

BETHESDA, Md., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Manolo Bellotto, Ph.D., General Manager and President at Gain, will present an overview on the Company’s proprietary Structurally Targeted Allosteric Regulators (STARs) for GM1 Gangliosidosis and Morquio B Disease.

GM1 Virtual Community Conference

Date: Tuesday, September 14th
Time: 2:00pm PT/5:00pm ET
Presenter: Manolo Bellotto, Ph.D., General Manager and President
To register to attend the conference visit https://registration.socio.events/e/gm1

Morquio B, also known as Mucopolysaccharidosis type IV (MPS IV), is a progressive disease mostly impacting the skeleton, caused by mutations in GLB1, the gene that encodes the beta-galactosidase (GLB) enzyme. GM1 Gangliosidosis is a hereditary, progressive disease mostly impacting neurons in the brain and spinal cord, caused by mutations in GLB1. In both diseases, these mutations result in the misfolding and subsequent dysfunction of GLB, which leads to toxic substrate accumulation in organs and tissues. Gain is developing allosteric regulators that are designed to decrease toxic substrate accumulation in organs and tissues of patients with Morquio B and GM1 Gangliosidosis in order to potentially provide the first treatment approach for the disease’s neurological symptoms.

About Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is positioned at the confluence of technology and healthcare and focused on redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding. Gain was established in 2017 with the support of its founders and institutional investors. It has been awarded funding support from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse. In July 2020, Gain Therapeutics, Inc. completed a share exchange with Gain Therapeutics, SA, a Swiss corporation, whereby GT Gain Therapeutics SA became a wholly owned subsidiary of Gain Therapeutics, Inc. For periods and at dates prior to the Corporate Reorganization, the consolidated financial statements were prepared based on the historical financial statements of GT Gain Therapeutics SA.

For more information, please visit https://www.gaintherapeutics.com

Forward-Looking Statements
Any statements in this release that are not historical facts may be considered to be “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Such statements include, but are not limited to, statements regarding the market opportunity for Gain’s product candidates, and the business strategies and development plans of Gain. Some of the potential risks and uncertainties that could cause actual results to differ from those expected include Gain’s ability to: make commercially available its products and technologies in a timely manner or at all; enter into strategic alliances, including arrangements for the development and distribution of its products; obtain intellectual property protection for its assets; accurately estimate and manage its expenses and cash burn and raise additional funds when necessary. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Gain does not undertake any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Investor & Media Contacts:
Gain Therapeutics Investor Contact:
Daniel Ferry
LifeSci Advisors
+1 (617) 430-7576
daniel@lifesciadvisors.com

Gain Therapeutics Media Contact:
Joleen Schultz
Joleen Schultz & Associates
+1 760-271-8150
joleen@joleenschultzassociates.com

https://www.globenewswire.com/newsroom/ti?nf=ODMyMzQ1NSM0Mzk4MzMwIzUwMDA3MzE2OA==
https://ml.globenewswire.com/media/MTMxYjg2OTktMDc0Yy00NjhkLTk3ZTUtZGRlMzY1OTlhMWE2LTUwMDA3MzE2OA==/tiny/Gain-Therapeutics.png

Source: Gain Therapeutics
👍️0
StockHighAlert- StockHighAlert- 3 years ago
$GANX News! Gain Therapeutics, Inc. Announces Positive Topline Data in Patient-derived iPSC Study Evaluating STAR Compounds as a Treatment for Gaucher and Parkinson’s Disease https://finance.yahoo.com/news/gain-therapeutics-inc-announces-positive-112900531.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
👍️0

Your Recent History

Delayed Upgrade Clock